---
title: "Palatin Technologies, Inc. (PTN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PTN.US.md"
symbol: "PTN.US"
name: "Palatin Technologies, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T13:17:31.527Z"
locales:
  - [en](https://longbridge.com/en/quote/PTN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PTN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PTN.US.md)
---

# Palatin Technologies, Inc. (PTN.US)

## Company Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [alatin.com](https://alatin.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:19.000Z

**Overall: B (0.28)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 55 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 3581.22% |  |
| Net Profit YoY | 73.21% |  |
| P/B Ratio | 2.44 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 25856383.41 |  |
| Revenue | 12884261.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -297.25% | E |
| Profit Margin | -48.50% | E |
| Gross Margin | 100.00% | A |
| Revenue YoY | 3581.22% | A |
| Net Profit YoY | 73.21% | A |
| Total Assets YoY | 254.71% | A |
| Net Assets YoY | 265.83% | A |
| Cash Flow Margin | 0.00% | D |
| OCF YoY | 3581.22% | A |
| Turnover | 1.52 | A |
| Gearing Ratio | 19.91% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Palatin Technologies, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "3581.22%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "73.21%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.44",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "25856383.41",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "12884261.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "-297.25%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-48.50%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "3581.22%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "73.21%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "254.71%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "265.83%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "3581.22%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "1.52",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "19.91%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.14 | 349/385 | - | - | - |
| PB | 2.44 | 216/385 | 75.40 | 3.56 | 3.05 |
| PS (TTM) | 2.01 | 48/385 | 4.28 | 3.78 | 3.19 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 67% |
| Overweight | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 14.59 |
| Highest Target | 60.00 |
| Lowest Target | 50.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/PTN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/PTN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/PTN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/PTN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**